文献速递泌尿男性生殖肿瘤支持与姑息治疗

镭-223三种给药方案治疗骨转移去势抵抗性前列腺癌的随机II期试验

A randomised phase II trial of three dosing regimens of radium-223 in patients with bone metastatic castration-resistant prostate cancer.
PubMed 文献 · Ann Oncol · 2019-12-23

该随机II期试验纳入391例骨转移性去势抵抗性前列腺癌患者,比较镭-223标准剂量、高剂量和延长疗程三种方案。结果显示高剂量或延长疗程均未改善无症状性骨骼事件生存期,且≥3级治疗中出现的不良事件更多。标准剂量方案仍是症状性mCRPC的标准治疗之一。

要点

  • 高剂量镭-223未改善SSE-FS,且≥3级TEAE发生率更高。
  • 延长疗程至12周期未改善SSE-FS,且更多患者因疾病进展无法完成。
  • 标准剂量55 kBq/kg每4周6周期仍是症状性mCRPC的标准治疗之一。

核心结论

  • 镭-223高剂量或延长疗程方案未改变SSE-FS或其他疗效终点,且与更多≥3级TEAE相关。

研究设计与样本

  • 随机II期试验,391例mCRPC骨转移患者按1:1:1随机分配至标准剂量、高剂量或延长疗程组。

主要发现

  • 标准剂量、高剂量和延长疗程组分别有37/130(28%)、42/130(32%)和48/131(37%)患者发生治疗中SSE。
  • 高剂量组与标准剂量组SSE-FS无统计学显著差异(中位12.9个月 vs 12.3个月;HR 1.06,80%CI 0.88-1.27,P=0.70)。
  • 延长疗程组与标准剂量组SSE-FS无统计学显著差异(中位10.8个月 vs 13.2个月;HR 1.26,80%CI 0.94-1.69,P=0.31)。
  • 三组总生存相似;≥3级TEAE在标准剂量、高剂量和延长疗程组分别影响34%、48%和53%的患者。

关键数值与推荐

  • 标准剂量:55 kBq/kg每4周一次,共6周期。
  • 高剂量:88 kBq/kg每4周一次,共6周期。
  • 延长疗程:55 kBq/kg每4周一次,共12周期。

临床怎么用

  • 对于症状性mCRPC骨转移患者,标准剂量镭-223(55 kBq/kg每4周6周期)仍是标准治疗选择之一。
  • 高剂量或延长疗程不推荐常规使用,因未改善疗效且毒性增加。

局限性

  • 延长疗程方案因疾病进展在较大比例患者中无法实施。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Radium-223 prolongs overall survival and delays symptomatic skeletal events (SSEs) in patients with metastatic castration-resistant prostate cancer (mCRPC) and bone metastases. The approved radium-223 regimen is 55 kBq/kg every 4 weeks (q4w) for six cycles (standard dose). We investigated different radium-223 regimens in patients with mCRPC. PATIENTS AND METHODS: Patients were randomised 1 : 1 : 1 to radium-223 standard-dose, high-dose (88 kBq/kg q4w for six cycles) or extended-schedule arms (55 kBq/kg q4w for 12 cycles). The primary end point, SSE-free survival (SSE-FS), was compared in patients treated with a high- versus standard-dose regimen, or with a standard dose in an extended (>6 to 12 cycles) versus standard schedule (six cycles). RESULTS: A total of 391 patients were randomised; baseline characteristics were balanced between arms. On-treatment SSEs developed in 37/130 (28%), 42/130 (32%) and 48/131 (37%) patients in the standard-dose, high-dose and extended-schedule arms, respectively. There was no statistically significant difference in SSE-FS in the high- versus standard-dose arms [median 12.9 months versus 12.3 months; hazard ratio (HR) 1.06, 80% confidence interval (CI) 0.88-1.27, P = 0.70], and in the extended- versus standard-schedule arms (median 10.8 months versus 13.2 months; HR 1.26, 80% CI 0.94-1.69, P = 0.31). Overall survival in the three treatment arms was similar. As many as 370 (95%) patients received treatment (median of six cycles) in each arm. Grade ≥3 treatment-emergent adverse events (TEAEs) affected 34% of patients in the standard-dose, 48% in the high-dose and 53% in the extended-schedule arm, causing permanent discontinuation in 9%, 16% and 17% of patients, respectively. CONCLUSION: Radium-223 high-dose or extended-schedule regimens resulted in no change in SSE-FS or other efficacy end points and were associated with more grade ≥3 TEAEs. The extended-schedule regimen (beyond six doses) could not be implemented in a large proportion of patients due to disease progression. Therefore, the standard-dose schedule remains one of the standard therapies for patients with symptomatic mCRPC. TRIAL REGISTRATION: ClinicalTrials.govNCT02023697.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Sternberg CN, Saad F, Graff JN, et al. A randomised phase II trial of three dosing regimens of radium-223 in patients with bone metastatic castration-resistant prostate cancer. Ann Oncol. 2019. PMID: 31959342. doi:10.1016/j.annonc.2019.10.025

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。